Azenta Life Sciences Announces Fiscal 2022 First Quarter Earnings Conference Call and Webcast

CHELMSFORD, Mass, Jan. 24, 2022/PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal 2022 first quarter earnings which ended on December 31, 2021on Tuesday, February 8, 2022after the market closes.

The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, February 8, 2022at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-584-1012 for domestic callers and +1-212-231-2907 for international callers.

Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ETon February 9, 2022.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December 1st, the company changed its name and ticker to Azenta, Inc. (Nasdaq: AZTA) from Brooks Automation, Inc, (Nasdaq: BRKS).

In addition, the company operates the Semiconductor Solutions Group business, an industry-leading provider of semiconductor manufacturing automation and collaborative robotics solutions worldwide. On September 20, 2021, the Company announced the pending sale of this business to Thomas H. Lee Partners. Due to the pending divestiture, the Company began reporting the Semiconductor Solutions Group business as discontinued operations in its fiscal year-end earnings announcement.

Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:

Sara Silverman
Director, Investor Relations
Azenta Life Sciences
978.262.2635
[email protected]

Sherry Dinsmore
Azenta Life Sciences
978.262.2400
[email protected]

SOURCE Azenta

Public link

Please use the above public link if you want to share this noodl on another website.